Cellular Biomedicine Gr (CBMG) Receives Coverage Optimism Score of 0.11

Press coverage about Cellular Biomedicine Gr (NASDAQ:CBMG) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellular Biomedicine Gr earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.522085481677 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of equities research analysts recently weighed in on the stock. Maxim Group cut shares of Cellular Biomedicine Gr from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. B. Riley restated a “buy” rating on shares of Cellular Biomedicine Gr in a research note on Friday, March 16th. ValuEngine upgraded shares of Cellular Biomedicine Gr from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Finally, BidaskClub upgraded shares of Cellular Biomedicine Gr from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th.

Shares of NASDAQ CBMG opened at $20.50 on Monday. Cellular Biomedicine Gr has a fifty-two week low of $5.05 and a fifty-two week high of $22.75. The stock has a market cap of $357.80, a P/E ratio of -11.52 and a beta of 3.47.

Cellular Biomedicine Gr (NASDAQ:CBMG) last issued its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.08). Cellular Biomedicine Gr had a negative net margin of 7,564.10% and a negative return on equity of 45.60%. The company had revenue of $0.07 million for the quarter. research analysts predict that Cellular Biomedicine Gr will post -1.62 EPS for the current year.

In related news, Director Wen Tao Liu sold 10,400 shares of Cellular Biomedicine Gr stock in a transaction dated Tuesday, April 10th. The shares were sold at an average price of $20.10, for a total transaction of $209,040.00. Following the sale, the director now directly owns 223,476 shares in the company, valued at $4,491,867.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 8.30% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Cellular Biomedicine Gr (CBMG) Receives Coverage Optimism Score of 0.11” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3381604/cellular-biomedicine-gr-cbmg-receives-coverage-optimism-score-of-0-11.html.

Cellular Biomedicine Gr Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.

Insider Buying and Selling by Quarter for Cellular Biomedicine Gr (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Gr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Gr and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Deutsche Bank AG Boosts Holdings in ContraFect
Deutsche Bank AG Boosts Holdings in ContraFect
Deutsche Bank AG Trims Stake in VOC Energy Trust
Deutsche Bank AG Trims Stake in VOC Energy Trust
IHS Markit  Shares Sold by Denver Investment Advisors LLC
IHS Markit Shares Sold by Denver Investment Advisors LLC
DekaBank Deutsche Girozentrale Acquires 2,289 Shares of Universal Forest Products
DekaBank Deutsche Girozentrale Acquires 2,289 Shares of Universal Forest Products
DekaBank Deutsche Girozentrale Purchases New Position in Summit Materials Inc
DekaBank Deutsche Girozentrale Purchases New Position in Summit Materials Inc
DekaBank Deutsche Girozentrale Invests $137,000 in Granite Construction Inc.  Stock
DekaBank Deutsche Girozentrale Invests $137,000 in Granite Construction Inc. Stock


© 2006-2018 Ticker Report. Google+.